Pediatrix Medical Group (NYSE:MD) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a report released on Wednesday morning.

Several other equities analysts have also recently weighed in on the company. Jefferies Financial Group lifted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. UBS Group increased their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Truist Financial increased their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Pediatrix Medical Group has a consensus rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Price Performance

MD opened at $14.15 on Wednesday. The firm’s fifty day moving average is $12.53 and its two-hundred day moving average is $9.85. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same quarter last year, the business posted $0.29 EPS. The firm’s revenue was up .9% compared to the same quarter last year. Equities research analysts forecast that Pediatrix Medical Group will post 1.25 earnings per share for the current year.

Insider Activity at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. This represents a 18.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,808 shares of company stock valued at $751,277. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter worth about $31,000. Innealta Capital LLC acquired a new stake in Pediatrix Medical Group during the 2nd quarter worth approximately $33,000. Quest Partners LLC lifted its holdings in Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares during the period. Finally, Quarry LP grew its holdings in Pediatrix Medical Group by 54.1% in the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after buying an additional 1,662 shares in the last quarter. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.